Phase 4
Completed N=20
Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)
Post-Traumatic Stress Disorder · Suicidal Ideation · Nightmares
Source: ClinicalTrials.gov NCT02199652 ↗
Enrolled (actual)
20
Serious AEs
10.0%
Results posted
Aug 2018
Primary outcomePrimary: Change Score for Scale for Suicide Ideation — 7.6; 8.2 units on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Patients with PTSD, and frequent nightmares, and mild-moderate suicidal ideation, who are already taking a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) will be randomized to either prazosin or placebo. The investigators hypothesize that patients receiving prazosin will have a greater reduction in suicidal ideation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change Score for Scale for Suicide Ideation |
7.6; 8.2 | — |
| SECONDARY Disturbing Dreams and Nightmare Severity Index |
9.75; 15.8 | — |
| SECONDARY Insomnia Severity Index |
10.7; 15.4 | — |
Eligibility Criteria
Inclusion Criteria
- PTSD
- Frequent nightmares
- Suicidality
Exclusion Criteria
- Schizophrenia
- Bipolar
- Substance abuse
Data sourced from ClinicalTrials.gov (NCT02199652). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.